Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Israel

European Innovation Council · Ended early

OVAL The OVAL study for VB-111 treatment of platinum-resistant ovarian cancer

Coordinator
Vascular Biogenics Ltd, Israel
Runs
1 April 2022 to 31 March 2024
Status
Ended early
EU funding
€2.5m
Total cost
€7.0m
Partners
1 organisations in 1 countries
Type
European Innovation Council
Grant agreement
190124455

What the project is doing

In the project's own words, from its summary on CORDIS.

VBL therapeutics is a late-stage clinical biopharmaceutical company focused on first in class treatments for cancer. VBL's lead oncology product candidate, VB-111, is an innovative targeted anti-cancer gene therapy with potential to treat a wide range of solid tumors. Most cancer therapies aim to target tumors cells while sparing normal cells, but tumors are heterogeneous and often develop resistance to treatment. Instead of targeting the tumor directly, VB-111 targets the tumor environment by disrupting the blood vessels that supply blood to the tumor and by recruiting the immune system into the tumor.

This dual mechanism of action together with an excellent safety profile make VB-111 a game-changer. VBL is pursuing Ovarian Cancer as the first indication for VB-111. In the scope of this project, VBL will to finalize a Phase 3 potential-registration clinical trial, the OVAL study as well as execute all the necessary steps towards final regulatory approvals and commercialization

Topics

Who is involved

OrganisationCityCountryRole
Vascular Biogenics LtdModiinIsraelCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI